

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 01	10296	Poster	Basic & Experimental 1	Jui-Chi Yu	Poly(ethylene Glycol)-Block-Poly(cysteine) Block Copolymer-Based Self-Assembling Nanoparticles Attenuate Oxidative Stress in Primary Human Hepatocytes	Friday September 18, 2026	17:00-17:36	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 01	10324	Poster	Basic & Experimental 1	Li-Wen Lin	Soat-Mediated Cholesterol Esterification Safeguards Against Hepatocyte Senescence and Inflammatory Sasp Activation	Friday September 18, 2026	17:00-17:36	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 01	10271	Poster	Basic & Experimental 1	Koji Fujita	Investigation of Metabolic Pathways Associated with Sensitivity to Multikinase Inhibitors in Hepatocellular Carcinoma	Friday September 18, 2026	17:00-17:36	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 01	10146	Poster	Basic & Experimental 1	Firman Alamsyah	The Effect of Electro-Capacitive Cancer Therapy on Liver Tumor Growth in Mice	Friday September 18, 2026	17:00-17:36	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 01	10353	Poster	Basic & Experimental 1	Wan-Chieh Li	Cross-Platform Transcriptomic Mapping for Conserved Molecular Axes of Disease Progression in Metabolic Dysfunction-Associated Steatotic Liver Disease	Friday September 18, 2026	17:00-17:36	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 01	10170	Poster	Basic & Experimental 1	Sachiyo Yoshio	Short-Term Exercise, But Not Bariatric Surgery, Reverses Cd4 + T-Cell Exhaustion in Severe Obesity and MASLD	Friday September 18, 2026	17:00-17:36	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 02	10083	Poster	Basic & Experimental 2	Hitoshi Iwasaki	Spp1/cd44 Axis and Slc7a11-Mediated Ferroptosis Resistance in Poor Tumor Necrosis After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma	Friday September 18, 2026	17:36-18:06	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 02	10135	Poster	Basic & Experimental 2	Che-Yu Hsu	Cytoplasmic Pla2 Contributes to Senescence-Mediated Lipid Accumulation in Primary Human Hepatocytes	Friday September 18, 2026	17:36-18:06	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 02	10101	Poster	Basic & Experimental 2	Daisuke Minowa	Exercise Improves Sarcopenia and Metabolic Dysfunction-Associated Steatohepatitis Through Activation of Skeletal Muscle Pgc-1 <i>β</i> /sirt1 Signaling	Friday September 18, 2026	17:36-18:06	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 02	10218	Poster	Basic & Experimental 2	Erdenetsogt Dungubat	Automated Quantification of Interlobular Bile Duct Loss in Whole-Slide Liver Images Using Deep Learning in a Mouse Model of Primary Biliary Cholangitis	Friday September 18, 2026	17:36-18:06	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 02	10049	Poster	Basic & Experimental 2	Sohji Nishina	Photothermally Modulated Liposome Enabling Efficient Release of 2-Deoxy-D-Glucose Safely Displays Vigorous Antitumor Effect Against Liver Cancer	Friday September 18, 2026	17:36-18:06	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 03	10209	Poster	Basic & Experimental 3	Hiroteru Kamimura	Effects of Voluntary Wheel Running on Hepatic Tissue and Skeletal Muscle in MASH Model Mice and Underlying Mechanisms	Friday September 18, 2026	17:00-17:30	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 03	10041	Poster	Basic & Experimental 3	Monirujjaman Biswas	Unveiling Glucose-Independent and Reversible Metabolic Pathways in Metformin's Anti-Proliferative Action on Liver Cancer Cells	Friday September 18, 2026	17:00-17:30	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 03	10189	Poster	Basic & Experimental 3	Tatsuo Kanda	Cabozantinib Could Inhibit Hepatitis a Replication in Human Hepatocytes	Friday September 18, 2026	17:00-17:30	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 03	10259	Poster	Basic & Experimental 3	Masashi Nakamura	Smyd2 Regulates Lymph Node Metastasis Derived from Intrahepatic Cholangiocellular Carcinoma Through Ccr7-Dependent Chemotaxis	Friday September 18, 2026	17:00-17:30	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 03	10252	Poster	Basic & Experimental 3	Tomoko Koda	Preliminary Analysis of Hepatic Pgc-1 <i>α</i> Expression Following Melatonin Administration in an Adenine-Induced Chronic Kidney Disease Mouse Model	Friday September 18, 2026	17:00-17:30	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 04	10097	Poster	Basic & Experimental 4	Yutao Dong	A Humanized Liver Mouse Model Supporting Hepatitis a Virus Infection and Antiviral Evaluation	Friday September 18, 2026	17:30-18:00	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 04	10377	Poster	Basic & Experimental 4	Sotaro Kurano	Spatial Transcriptomic Identification of an Inflammatory Tumor Microenvironment in HBsAg Transgenicmice with Diet-Induced MASH	Friday September 18, 2026	17:30-18:00	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 04	10290	Poster	Basic & Experimental 4	Yi-Hsuan Li	Exercise-Induced Changes in Serum Extracellular Vesicle-Associated Oxidative Status in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease	Friday September 18, 2026	17:30-18:00	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 04	10089	Poster	Basic & Experimental 4	Anand Krishna Singh	Therapeutic Synergy of Sestrin Ampk Pathway and Sglt 2 Inhibitors from Soybean Glycine Max in Type 2 Diabetes Associated Hepatic Dysfunction	Friday September 18, 2026	17:30-18:00	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 04	10014	Poster	Basic & Experimental 4	Wei-Yu Kao	Sustained High-Fat Diet Intake Differentially Regulates Hepatic Lipophagy and Metabolic Adaptation after Bariatric Surgery in Obese Rats	Friday September 18, 2026	17:30-18:00	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 05	10139	Poster	Basic & Experimental 5	Bao V Tran	Therapeutic Potential of Recombinant Human Cytoglobin in Acetaminophen-Induced Hepatotoxicity: Evidence from in Vivo and Transcriptomic Analyses	Friday September 18, 2026	18:00-18:30	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 05	10336	Poster	Basic & Experimental 5	Mitsuki Ishida	Porto-Sinusoidal Vascular Disorder as a Cause of Non-Cirrhotic Portal Hypertension in a Patient with Rheumatoid Arthritis on Long-Term Methotrexate and Igaratimod	Friday September 18, 2026	18:00-18:30	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 05	10028	Poster	Basic & Experimental 5	Bibek Thapa	Community-Led Harm Reduction Pathways to End Hepatitis C Elimination Barriers Among People Who Use Drugs in Nepal	Friday September 18, 2026	18:00-18:30	18:12	18:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 05	10227	Poster	Basic & Experimental 5	Yu-Ching Huang	Tryptophan Metabolites Attenuates Liver Fibrosis by Modulating Hepatic Stellate Cell Status and Restoring Mitochondrial Dynamics in Masld/mash	Friday September 18, 2026	18:00-18:30	18:18	18:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 05	10116	Poster	Basic & Experimental 5	Minsun Kim	Machine Learning Model for HCC Risk Prediction in MASLD Patients Using Fibroscan and Emr Data	Friday September 18, 2026	18:00-18:30	18:24	18:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 06	10233	Poster	Basic & Experimental 6	Kotaro Kumagai	Gpnmb Drives Macrophage-Mediated Immune Suppression and T Cell Dysfunction in Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 06	10351	Poster	Basic & Experimental 6	Wu Chang	Hepatocyte-Specific Flcn Deficiency Attenuates Mash-Associated Hepatocarcinogenesis	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 06	10206	Poster	Basic & Experimental 6	Nisrin Binti Abd Kadir	Pesticide-Induced Oxidative Stress in Rice (Oryza Sativa L Cv Mr263): a Possible Link to Hepatotoxic Risk in Consumers	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 06	10369	Poster	Basic & Experimental 6	Pardeep Kumar	Machine Learning Based Analysis of Epigenetic Signatures in Pediatric Malnutrition: Histone Modification Patterns Associated with Liver Dysfunction and Growth Outcomes	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 06	10286	Poster	Basic & Experimental 6	Mitsuki Ishida	Methotrexate-Induced Portosinusoidal Vascular Disorder Presenting with Splenomegaly and Periumbilical Varices in a Rheumatoid Arthritis Patient: Confirmation by Drug-Induced Lymphocyte Stimulation Test	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 07	10030	Poster	Basic & Experimental 7	Jie Yu	Betaine Homocysteine Methyltransferase Attenuates Metabolic Dysfunction-Associated Steatohepatitis by Inhibiting Notch4-Hes1 Pathway	Saturday September 19, 2026	15:30-15:54	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 07	10071	Poster	Basic & Experimental 7	Bui Tam Chi Nguyen	Single-Cell Transcriptomic Analysis Identifies Ccbe1 as a Novel Hsc Quiescence Marker Restored by Cytoglobin in Liver Fibrosis	Saturday September 19, 2026	15:30-15:54	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 07	10070	Poster	Basic & Experimental 7	Saima Mushtaq	Targeting Hbx in Hbv-Related HCC Through In-Silico and Crispr Approaches	Saturday September 19, 2026	15:30-15:54	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 07	10112	Poster	Basic & Experimental 7	Suzuki Takuto	Impact of Dgk ζ Deficiency on Liver Fibrosis in a MASLD Mouse Model	Saturday September 19, 2026	15:30-15:54	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 08	10065	Poster	HCC 1	Shih-Chieh Chien	Dynamic Change of New-Generation Tumor Markers in Predicting Recurrence of Hepatocellular Carcinoma Following Curative Treatment	Friday September 18, 2026	17:00-17:30	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 08	10348	Poster	HCC 1	Hung Chih Chiu	Real-World Outcomes of First-Line Stride for Unresectable HCC	Friday September 18, 2026	17:00-17:30	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 08	10120	Poster	HCC 1	Hironao Okubo	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients with Unresectable Hepatocellular Carcinoma in Early Clinical Practice: a Multicenter Analysis	Friday September 18, 2026	17:00-17:30	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 08	10372	Poster	HCC 1	Vikas Sharma	Telemedicine Based Supportive Oncology for Managing Sleep Disturbance and Anxiety in Pediatric Liver Cancer	Friday September 18, 2026	17:00-17:30	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 08	10168	Poster	HCC 1	Tingyu Lin	Gastrointestinal Bleeding Risk and the Value of Endoscopic Assessment in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab	Friday September 18, 2026	17:00-17:30	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 09	10201	Poster	HCC 2	Masakuni Tateyama	Development of Hepatocellular Carcinoma After the Eradication of Hepatitis C Virus by Direct-Acting Antivirals and Outcome of the Patients with Sustained Virological Response	Friday September 18, 2026	17:30-18:06	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 09	10374	Poster	HCC 2	Haruhiko Takeda	Clinical Utility and Limitations of Comprehensive Genomic Profiling in Immunotherapy-Treated Advanced Hepatocellular Carcinoma: Insights from Multi-Omics Analysis	Friday September 18, 2026	17:30-18:06	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 09	10131	Poster	HCC 2	Yu Akazawa	Long-Term Prognostic Impact of Immune-Mediated Hepatitis in Patients Receiving Immune Checkpoint Inhibitors	Friday September 18, 2026	17:30-18:06	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 09	10184	Poster	HCC 2	Daiki Maeda	Early AFP Reduction Predicts Conversion Therapy and Long-Term Survival in Br2 Hepatocellular Carcinoma	Friday September 18, 2026	17:30-18:06	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 09	10302	Poster	HCC 2	Yuki Minetoma	Durable Drug-Free Complete Response to Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma with Major Portal Vein Invasion After Managing Portal Hypertension: a Case-Based Cohort Analysis	Friday September 18, 2026	17:30-18:06	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 09	10152	Poster	HCC 2	Hery Djagat Purnomo	One in Five Hepatocellular Carcinomas Are Afp-Negative: Clinical Characteristics and Prognostic Implications from Six-Year Indonesian Study	Friday September 18, 2026	17:30-18:06	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 10	10338	Poster	HCC 3	Makoto Chuma	Clinical Significance of Circulating Biomarkers of Immune Checkpoint Molecules with Atezolizumab Plus Bevacizumab Therapy in Unresectable Hepatocellular Carcinoma	Friday September 18, 2026	18:06-18:36	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 10	10350	Poster	HCC 3	Erdenebayar Gonchig	Patterns of Extrahepatic Metastasis in Hepatocellular Carcinoma	Friday September 18, 2026	18:06-18:36	18:12	18:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 10	10231	Poster	HCC 3	Takao Shimizu	Real-World Outcomes of Short-Course Len-Tace Sequential Therapy for Intermediate-Stage Hepatocellular Carcinoma	Friday September 18, 2026	18:06-18:36	18:18	18:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 10	10173	Poster	HCC 3	Hidekazu Yamamoto	Clinical Outcomes of Conversion Surgery Following Immune Checkpoint Inhibitor Therapy in Patients with Advanced Hepatocellular Carcinoma	Friday September 18, 2026	18:06-18:36	18:24	18:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 10	10176	Poster	HCC 3	Takeshi Matsui	Clinical Characteristics of Patients with Spontaneous Rupture of Hepatocellular Carcinoma at a Single Center	Friday September 18, 2026	18:06-18:36	18:30	18:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 11	10332	Poster	HCC 4	Daigo Mamitsuka	Clinical Outcomes of Durvalumab Plus Tremelimumab for Advanced Hepatocellular Carcinoma: a Case Series Highlighting an Exceptional Response in Concomitant Mss Colorectal Cancer	Friday September 18, 2026	17:00-17:36	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 11	10246	Poster	HCC 4	Hiroaki Matsumoto	Early Real-World Experience with Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma: a Single-Center Experience in Japan	Friday September 18, 2026	17:00-17:36	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 11	10278	Poster	HCC 4	Yoshinari Asaoka	Efficacy and Severe Iraes of First-Line Nivolumab Plus Ipilimumab for Advanced Hepatocellular Carcinoma: a Case Series	Friday September 18, 2026	17:00-17:36	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 11	10216	Poster	HCC 4	Oyunselenge B	Association of Hba1c with Liver Steatosis and Fibrosis	Friday September 18, 2026	17:00-17:36	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 11	10075	Poster	HCC 4	Habib M Sazzad	Observation of Six Months Outcome of Hepatocellular Carcinoma Patients with First Line Systemic Treatment on the Basis of Etiology	Friday September 18, 2026	17:00-17:36	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 11	10080	Poster	HCC 4	Hideaki Miyamoto	Regimen-Specific Immune-Related Adverse Event Profiles in Patients Receiving Io-Io Combination Therapy	Friday September 18, 2026	17:00-17:36	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 12	10314	Poster	HCC 5	Jun Arai	Efficacy of Scheduled Lenvatinib Plus TACE for Intermediate-Stage, Tace-Unsuitable Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:36	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 12	10025	Poster	HCC 5	Mi Na Kim	The Impact of Alcohol Consumption on the Risk of Hepatocellular Carcinoma Across Different Age Groups: a Nationwide Cohort Study	Saturday September 19, 2026	15:00-15:36	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 12	10072	Poster	HCC 5	Minjeong Kang	Efficacy and Safety of Adding Radiotherapy to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis	Saturday September 19, 2026	15:00-15:36	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 12	10234	Poster	HCC 5	Miuzki Endo	Long-Term Investigation of Hepatocarcinogenesis in Patients with Type 2 Diabetes Mellitus: a 20-Year Prospective Cohort Study	Saturday September 19, 2026	15:00-15:36	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 12	10291	Poster	HCC 5	Asahiro Morishita	PD-L1 Gene Polymorphisms as Predictive Biomarkers for Immune Checkpoint Inhibitor Combination Therapy in Unresectable Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:36	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 12	10371	Poster	HCC 5	Yoshie Kadota	Radiofrequency Ablation for Suspected Hepatocellular Carcinoma in a Patient with Hepatitis C-Related Cirrhosis and Situs Viscerum Inversus After the Fontan Procedure: a Case Report	Saturday September 19, 2026	15:00-15:36	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 13	10088	Poster	HCC 6	Ko Hashimoto	Early Changes in AFP and Dep Predict Response to Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma: a Multicenter Retrospective Study	Saturday September 19, 2026	15:36-16:12	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 13	10298	Poster	HCC 6	Sho Ijuin	Prognostic Impact of Nutritional Assessment Markers in Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab	Saturday September 19, 2026	15:36-16:12	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 13	10199	Poster	HCC 6	Hironao Okubo	Treatment of Unresectable Hepatocellular Carcinoma with Cabozantinib in the Era of Immunotherapy: Importance of Treatment Sequence	Saturday September 19, 2026	15:36-16:12	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 13	10310	Poster	HCC 6	Keisuke Koroki	Comparative Analysis of Immune-Mediated Adverse Events and Early Efficacy of Durvalumab + Tremelimumab and Nivolumab + Ipilimumab in Advanced Hepatocellular Carcinoma	Saturday September 19, 2026	15:36-16:12	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 13	10153	Poster	HCC 6	Toshinori Toyota	Treatment-Related Skeletal Muscle Loss During Systemic Therapy: a Multicenter Comparison of Atezolizumab Bevacizumab and Lenvatinib in Unresectable Hepatocellular Carcinoma	Saturday September 19, 2026	15:36-16:12	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 13	10261	Poster	HCC 6	Riku Nakashima	Clinical Outcomes of Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma: a Single-Center Retrospective Study	Saturday September 19, 2026	15:36-16:12	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 14	10001	Poster	HCC 7	Hiraoka Atsushi	Interaction Between Simplified Balad Score and Treatment Efficacy of Immune Checkpoint Inhibitor Regimens in Unresectable Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:36	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 14	10320	Poster	HCC 7	Shohei Shiota	Characteristics of Ruptured Liver Cancer Cases Experienced over the Past Year	Saturday September 19, 2026	15:00-15:36	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 14	10217	Poster	HCC 7	Amarsanaa Jazag	A-Hoc Study on Patients under Surveillance for Liver Cancer in Mongolia	Saturday September 19, 2026	15:00-15:36	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 14	10214	Poster	HCC 7	Anujin Chinzorig	Mongolian National University of Medical Sciences	Saturday September 19, 2026	15:00-15:36	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 14	10346	Poster	HCC 7	Kenta Yamamoto	Gut Microbiota-Enhanced Survival Stratification in Hypervascular Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:36	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 14	10150	Poster	HCC 7	Satoshi Narahara	The Harmony Index: an Early Predictor of Primary Resistance to Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:36	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 15	10253	Poster	HCC 8	Kyoko Oura	Clinical Impact of Sarcopenia Diagnosed Using Handgrip Strength and Skeletal Muscle Index in Patients with Hepatocellular Carcinoma Receiving Combination Immunotherapy	Saturday September 19, 2026	15:36-16:12	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 15	10322	Poster	HCC 8	Akihiro Deguchi	Clinical Impact of Incorporating New Fp Hepatic Arterial Infusion Chemotherapy into the Sequential Treatment Strategy After Combination Immunotherapy for Unresectable Hepatocellular Carcinoma	Saturday September 19, 2026	15:36-16:12	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 15	10118	Poster	HCC 8	Chinatsu Nishioka	Real-World Efficacy and Safety of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma: a Multicenter Cohort Study	Saturday September 19, 2026	15:36-16:12	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 15	10316	Poster	HCC 8	Yutaro Hori	Verification of the Therapeutic Effect of Dual Immune Checkpoint Inhibitor for Advanced Hepatocellular Carcinoma Using Previously Reported Treatment Effect Predictors	Saturday September 19, 2026	15:36-16:12	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 15	10042	Poster	HCC 8	Monirujjaman Biswas	Efficient Deep Learning Framework for Nucleus Segmentation from the Histopathological Images in Liver Cancer	Saturday September 19, 2026	15:36-16:12	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 15	10190	Poster	HCC 8	Ariunzaya Munkhchuluun	Comparison of Bevacizumab Treatment Outcomes by Hepatitis Virus Infection, Gender, and Age Group	Saturday September 19, 2026	15:36-16:12	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 16	10352	Poster	Hepato-Biliary Disease 1	Erdenebayar Gonchig	Patterns of Liver Metastasis from Extrahepatic Primary Malignancies	Friday September 18, 2026	17:36-18:12	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 16	10040	Poster	Hepato-Biliary Disease 1	Monirujjaman Biswas	Exploratory and Predictive Analytics of Covid-19's Impact on Liver Cancer Outcomes	Friday September 18, 2026	17:36-18:12	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 16	10368	Poster	Hepato-Biliary Disease 1	Pardeep Kumar	Agricultural Exposure to Organic Fungicides and Herbicides and the Risk of Cholangiocarcinoma in Rural Agricultural Workers	Friday September 18, 2026	17:36-18:12	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 16	10069	Poster	Hepato-Biliary Disease 1	Saima Mushtaq	Viral Persistence in Hepatitis-Associated Hepatocellular Carcinoma: Translational Evidence from Liver Tissues	Friday September 18, 2026	17:36-18:12	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 16	10255	Poster	Hepato-Biliary Disease 1	Shuntaro Obi	Adding Afp-L3 and Dcp to AFP Enables Detection Very Small HCC: Validation with A-Hoc Study	Friday September 18, 2026	17:36-18:12	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 16	10066	Poster	Hepato-Biliary Disease 1	Tagayasu Yoshiyuki	S100p Immunohistochemistry Underpins Prognostic and Molecular Stratification in Intrahepatic Cholangiocarcinoma	Friday September 18, 2026	17:36-18:12	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 17	10272	Poster	Hepato-Biliary disease 2	Hiroumi Akita	Factors Associated with Long-Term Survival in Intrahepatic Cholangiocarcinoma: a Single-Center Real-World Analysis	Saturday September 19, 2026	15:00-15:24	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 17	10136	Poster	Hepato-Biliary disease 2	Tomoaki Yoh	Evolution of Treatment Strategies and the Impact of Major Pathological Response in Borderline Resectable Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:24	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 17	10331	Poster	Hepato-Biliary disease 2	Tomoaki Emori	Efficacy, Safety, and Genomic Profiling of Gcd/gcp Therapy for Unresectable Intrahepatic Cholangiocarcinoma: a Real-World Study	Saturday September 19, 2026	15:00-15:24	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 17	10329	Poster	Hepato-Biliary disease 2	Tomotake Shirono	Treatment Outcomes and Prognostic Analysis in Unresectable Intrahepatic Cholangiocarcinoma: a Multicenter Retrospective Study Using Real-World Data	Saturday September 19, 2026	15:00-15:24	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 18	10367	Poster	Hepato-Biliary disease 3	Pardeep Kumar	Diagnostic Relevance of Neutrophil Gelatinase-Associated Lipocalin in Cholangiocarcinoma and Biliary Tract Cancers Among Elderly Patients	Saturday September 19, 2026	15:24-15:54	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 18	10043	Poster	Hepato-Biliary disease 3	Monirujjaman Biswas	Diagnostic Approach to Histomorphological and Immunohistochemical Spectrum of Metastatic Liver Lesions	Saturday September 19, 2026	15:24-15:54	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 18	10107	Poster	Hepato-Biliary disease 3	Keita Shirahata	Cholangioscopy for Intrahepatic Iopn with Invasive Carcinoma: a Case Report	Saturday September 19, 2026	15:24-15:54	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 18	10140	Poster	Hepato-Biliary disease 3	Kentaro Sato	A Diagnostically Challenging Case of Intrahepatic Cholangiocarcinoma with Surrounding Peribiliary Cysts	Saturday September 19, 2026	15:24-15:54	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 18	10171	Poster	Hepato-Biliary disease 3	Naoshi Odagiri	Association of Serum Full-Length Glypican-3 with Clinical Outcomes in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab	Saturday September 19, 2026	15:24-15:54	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 19	10095	Poster	Diagnosis (Imaging & Biomarkers)	Beta Canina Harlyjoy	Vascular Remodelling During Liver Fibrosis Progression and Regression	Saturday September 19, 2026	15:54-16:24	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 19	10299	Poster	Diagnosis (Imaging & Biomarkers)	Michitaka Matsuda	Intratumor Immunofibrosis Profile Associated with Hepatocellular Carcinoma Recurrence	Saturday September 19, 2026	15:54-16:24	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 19	10114	Poster	Diagnosis (Imaging & Biomarkers)	Yuzuru Sakamoto	Serum Soluble Siglec-5 Is a Prognostic Biomarker in Patients with Hepatocellular Carcinoma	Saturday September 19, 2026	15:54-16:24	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 19	10215	Poster	Diagnosis (Imaging & Biomarkers)	Erdenebayar Gonchig	Association Between Glycemic Control (Hba1c) and Liver Transaminase Levels (ALT and AST)	Saturday September 19, 2026	15:54-16:24	16:12	16:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 19	10210	Poster	Diagnosis (Imaging & Biomarkers)	Khongorzul E	Correlation Between Liver Biomarkers and Hemoglobin Levels	Saturday September 19, 2026	15:54-16:24	16:18	16:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 20	10305	Poster	Hepatitis & Chronic Liver Disease 1	Akio Moriya	Factors Associated with Alanine Aminotransferase Improvement After Initiation of Tirzepatide in Patients with Type 2 Diabetes	Friday September 18, 2026	17:00-17:36	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 20	10328	Poster	Hepatitis & Chronic Liver Disease 1	Minkyoung Gu	Ai-Based Integrative Analysis of Alcohol Associated Liver Injury	Friday September 18, 2026	17:00-17:36	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 20	10323	Poster	Hepatitis & Chronic Liver Disease 1	Ariunaa Baljinnyam	The Effect of Semaglutide on Weight Loss and Liver Fat Reduction in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	Friday September 18, 2026	17:00-17:36	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 20	10244	Poster	Hepatitis & Chronic Liver Disease 1	Tatia Khachidze	A Narrative Review of the Diagnostic Performance of Non-Invasive Scoresfor Predicting Fibrosis in MaflD	Friday September 18, 2026	17:00-17:36	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 20	10177	Poster	Hepatitis & Chronic Liver Disease 1	Satoru Kakizaki	The Fib-3 Index Outperforms Fib-4 and Shows Comparable Prognostic Performance to Amap and Meld in Patients with Hepatic Encephalopathy Receiving Rifaximin: a Multicenter Retrospective Analysis	Friday September 18, 2026	17:00-17:36	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 20	10342	Poster	Hepatitis & Chronic Liver Disease 1	Makiko Taniai	Clinical Aspects of Hepatocellular Carcinoma in Autoimmune Liver Diseases	Friday September 18, 2026	17:00-17:36	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 21	10262	Poster	Hepatitis & Chronic Liver Disease 2	Xin Zheng	Identification of Novel Antiviral Agent Against Hepatitis a Virus Replication	Friday September 18, 2026	17:36-18:06	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 21	10276	Poster	Hepatitis & Chronic Liver Disease 2	Doaa A Abo Elwafa	Enhanced Suppression of Hepatitis D Virus Infection by a Newly Developed Rxr Agonist Targeting Ntcp Mediated Viral Entry	Friday September 18, 2026	17:36-18:06	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 21	10220	Poster	Hepatitis & Chronic Liver Disease 2	Amarsanaa Jazag	Study on Patients Undergoing Triple Therapy for Liver Steatosis in Mongolia	Friday September 18, 2026	17:36-18:06	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 21	10024	Poster	Hepatitis & Chronic Liver Disease 2	Mi Na Kim	Effect of Diabetes on the Risk of Fibrosis Progression in Patients with Chronic Hepatitis B	Friday September 18, 2026	17:36-18:06	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 21	10195	Poster	Hepatitis & Chronic Liver Disease 2	Harsha Vardhan Manjunatha	Efficacy and Safety of Combining Immune Checkpoint Inhibitors with Transarterial Radioembolization in Advanced/unresectable Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis	Friday September 18, 2026	17:36-18:06	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 22	10204	Poster	Hepatitis & Chronic Liver Disease 3	Tatsunori Kondo	A Case of Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome Associated with Immune Thrombocytopenia	Friday September 18, 2026	18:06-18:36	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 22	10269	Poster	Hepatitis & Chronic Liver Disease 3	Misaki Matsui	Radiotherapy (Rt) for Hepatocellular Carcinoma at Our Institution	Friday September 18, 2026	18:06-18:36	18:12	18:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 22	10013	Poster	Hepatitis & Chronic Liver Disease 3	Vu Van Khien	Efficacy and Safety of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Vietnam	Friday September 18, 2026	18:06-18:36	18:18	18:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 22	10145	Poster	Hepatitis & Chronic Liver Disease 3	Ruba Chakma	Seroprevalence of Hepatitis E Virus Exposure Among Patients with Hepatocellular Carcinoma in Chiang Mai, Thailand	Friday September 18, 2026	18:06-18:36	18:24	18:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 22	10172	Poster	Hepatitis & Chronic Liver Disease 3	Anfal Abdelazeim Abbass Taifour	Hemochromatosis Presenting with Severe Jaundice, Arthralgia, Amenorrhea, and Bronze Skin Pigmentation Mimicking Acute Viral Hepatitis :a Case Report	Friday September 18, 2026	18:06-18:36	18:30	18:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 23	10144	Poster	Hepatitis & Chronic LiverDisease 4	Rama_maleakhi Saragih	Differential Associations of Hepatic Steatosis, Metabolic Dysfunction, and Steatohepatitis with Hepatocellular Carcinoma Risk in Chronic Hepatitis B: a Systematic Review and Meta-Analysis	Saturday September 19, 2026	15:00-15:36	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 23	10063	Poster	Hepatitis & Chronic LiverDisease 4	Md Farhad Hossen	Perceptions and Awareness of Non-Alcoholic Fatty Liver Disease at the Community Level in Bangladesh a Cross-Sectional Study	Saturday September 19, 2026	15:00-15:36	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 23	10166	Poster	Hepatitis & Chronic LiverDisease 4	Harshita Dubey	Chemotherapy Induced Hepatic Steatosis in Ovarian Cancer	Saturday September 19, 2026	15:00-15:36	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 23	10004	Poster	Hepatitis & Chronic LiverDisease 4	Eihmile Kreistein N Salgado	The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Using Sonographic Qualitative Assessment Among Filipino Patients with Metabolic Syndrome in a Tertiary Hospital in Iloilo City: a Pilot Study	Saturday September 19, 2026	15:00-15:36	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 23	10373	Poster	Hepatitis & Chronic LiverDisease 4	Ankush Kumar	Central Obesity, Insulin Resistance, and Ldl Cholesterol in Middle-Aged Women with Nonalcoholic Fatty Liver Disease: Implications for Progression to Advanced Liver Disease	Saturday September 19, 2026	15:00-15:36	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 23	10019	Poster	Hepatitis & Chronic LiverDisease 4	Arjun Maria	Development and Validation of an AI Driven Convolutional Neural Network for Automated Stool Colour Classification to Facilitate Early Diagnosis of Biliary Atresia	Saturday September 19, 2026	15:00-15:36	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 24	10044	Poster	Hepatitis & Chronic LiverDisease 5	Natsumi Tsukano	Steatotic Liver Disease During Steroid Therapy in Patients with Autoimmune Hepatitis and Its Associated Factors	Saturday September 19, 2026	15:36-16:06	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 24	10053	Poster	Hepatitis & Chronic LiverDisease 5	Demver P Gomez	Finite Versus Indefinite Nucleos(t)ide Analogue Therapy in Hbeag-Negative Chronic Hepatitis B: Meta-Analysis of Randomized Trials	Saturday September 19, 2026	15:36-16:06	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 24	10363	Poster	Hepatitis & Chronic LiverDisease 5	Keisuke Ishigami	Igm-Positive Plasma Cell Tubulointerstitial Nephritis in Patients Diagnosed with Autoimmune Hepatitis and Elevated Serum Igm Levels	Saturday September 19, 2026	15:36-16:06	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 24	10222	Poster	Hepatitis & Chronic LiverDisease 5	Erdenebayar Gonchig	Age-Specific Prevalence of Viral Hepatitis in Mongolia	Saturday September 19, 2026	15:36-16:06	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 24	10109	Poster	Hepatitis & Chronic LiverDisease 5	Anand Krishna Singh	Synergistic Effects of Withania Somnifera Alkaloid Extract and Metformin on Hepatic Ultrastructure and Biochemistry in a NAFLD Model	Saturday September 19, 2026	15:36-16:06	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 25	10183	Poster	Hepatitis & Chronic LiverDisease 6	Aswanth Ks	Calfan Syndrome: an Unusual Cause of Infantile Acute-On-Chronic Liver Failure	Saturday September 19, 2026	16:06-16:36	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 25	10054	Poster	Hepatitis & Chronic LiverDisease 6	Yasuhiko Nakao	Noninvasive Prediction of Serum Bilirubin via Scleral Color Analysis: Clinical Validation of the Lab B-Channel as a Practical Biomarker for Jaundice Screening	Saturday September 19, 2026	16:06-16:36	16:12	16:18	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 25	10022	Poster	Hepatitis & Chronic LiverDisease 6	Khiem K Pham	Primary Biliary Cholangitis in Vietnam: Heterogeneous Biochemical Patterns and a High Proportion of Ama-Negative Cases	Saturday September 19, 2026	16:06-16:36	16:18	16:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 25	10192	Poster	Hepatitis & Chronic LiverDisease 6	Erdenebayar Gonchig	Declining Trends of Hepatitis Virus Prevalence in Mongolia: an Analysis Based on Early Detection Data	Saturday September 19, 2026	16:06-16:36	16:24	16:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 25	10334	Poster	Hepatitis & Chronic LiverDisease 6	Hyunjin Jeong	Loss of Erdj5 Drives Sorafenib Resistance in Hepatocellular Carcinoma by Regulating Gpx4-Dependent Ferroptosis	Saturday September 19, 2026	16:06-16:36	16:30	16:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 26	10211	Poster	Clinical and Translational Hepatology 1	Ryoko Asari	Early Real-World Experience Integrating Point-Of-Care Hbeag-Hs Rapid Testing into Routine Antenatal Services for HBV Pmtct in the Gambia	Friday September 18, 2026	17:00-17:36	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 26	10287	Poster	Clinical and Translational Hepatology 1	Kazunari Tanaka	Clinical Impact of Beta-D-Glucan Positivity in Patients with Acute Liver Failure	Friday September 18, 2026	17:00-17:36	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 26	10020	Poster	Clinical and Translational Hepatology 1	Arjun Maria	Impact of Continuous Renal Replacement Therapy on Survival and Ammonia Clearance in Hepatitis a Virus Associated Pediatric Acute Liver Failure with Advanced Hepatic Encephalopathy: a Two-Centre Retrospective Cohort Analysis	Friday September 18, 2026	17:00-17:36	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 26	10266	Poster	Clinical and Translational Hepatology 1	Shunhei Yamashina	Cathepsin L Inhibitor Enhances Liver Regeneration in Fibrotic Liver	Friday September 18, 2026	17:00-17:36	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 26	10319	Poster	Clinical and Translational Hepatology 1	Sourav Kumar Chakraborty	TACE Plus Lenvatinib Improves Objective Response and Downstaging Within Ucsf Criteria in Treatment-Naive Unresectable HCC: a Comparative Study	Friday September 18, 2026	17:00-17:36	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 26	10165	Poster	Clinical and Translational Hepatology 1	Asgar Ali	Pten as a Diagnostic and Prognostic Biomarker in Periampullary Cancer: a Tissue-Based Molecular Study from India	Friday September 18, 2026	17:00-17:36	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 27	10091	Poster	Clinical and Translational Hepatology 2	Takahiro Mizuta	Impact of Hepatic Steatosis on Lsm-Based Cirrhosis Assessment and Ckd Risk Stratification in MASLD	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 27	10229	Poster	Clinical and Translational Hepatology 2	Hirayuki Enomoto	Hepatoma-Derived Growth Factor as a Potential Therapeutic Target for Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 27	10055	Poster	Clinical and Translational Hepatology 2	Mohammad Khairul Basher	Comparison of Epidemiological, Biochemical, and Radiological Characteristics Between Viral and Non-Viral Etiology of Hepatocellular Carcinoma Patients	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 27	10308	Poster	Clinical and Translational Hepatology 2	Fatimah Abd Kadir	Photocatalytic Degradation of Methylene Blue to Mitigate Liver Disease: a Step Toward Sustainable Wastewater Treatment	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 27	10223	Poster	Clinical and Translational Hepatology 2	Tomoko Aoki	Stromal-Rich Tumor Immune Microenvironment in Fdg-Pet-Positive Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 28	10056	Poster	MASLD/ MAFLD and ALD 1	Trang Diep Thanh Le	Feasibility of Deep Learning-Based Automated Histopathological Scoring for Metabolic Dysfunction-Associated Steatohepatitis (MASH): a Pilot Study	Friday September 18, 2026	17:36-18:12	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 28	10010	Poster	MASLD/ MAFLD and ALD 1	Eisuke Murakami	Association of the Elf Score with Liver-Related Complications and Cardiovascular Events in Metabolic Dysfunction-Associated Steatohepatitis	Friday September 18, 2026	17:36-18:12	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 28	10343	Poster	MASLD/ MAFLD and ALD 1	Chia-Yang Li	Genomic Signatures Associated with Different Stages of Fibrosis in MASLD and Semaglutide Treatment Effects	Friday September 18, 2026	17:36-18:12	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 28	10035	Poster	MASLD/ MAFLD and ALD 1	Taketo Fukuoka	A Novel Abca1 Mutation in Shrsp5/dmcr Rats Promotes MASH via Hepatic Free Cholesterol Overload and Nlrp3 Inflammasome Activation	Friday September 18, 2026	17:36-18:12	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 28	10330	Poster	MASLD/ MAFLD and ALD 1	Jumpei Okamura	Impact of Alcohol Intake on the Efficacy of a Moderate-Carbohydrate Diet in Patients with MASLD	Friday September 18, 2026	17:36-18:12	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 28	10254	Poster	MASLD/ MAFLD and ALD 1	Takemi Akahane	Serum Cytokeratin-18 Fragment Refines Fib-4 Index-based Risk Stratification for At-Risk MASH	Saturday September 19, 2026	17:36-18:12	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 29	10137	Poster	MASLD/ MAFLD and ALD 2	Lian-Wang Cai	Extracellular Vesicle Biomarkers Enhance Machine Learning Classification of Obese and Lean Metabolic Dysfunction-Associated Steatotic Liver Disease	Friday September 18, 2026	18:12-18:48	18:12	18:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 29	10347	Poster	MASLD/ MAFLD and ALD 2	Adinda Amalia	Beyond Baveno Vii Non-Invasive Criteria: Eus-Ppg Confirmed Clinically Significant Portal Hypertension in MASLD with Low Liver Stiffness	Friday September 18, 2026	18:12-18:48	18:18	18:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 29	10219	Poster	MASLD/ MAFLD and ALD 2	Tomomi Kogiso	Association Between Hepatic Steatosis and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B	Friday September 18, 2026	18:12-18:48	18:24	18:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 29	10017	Poster	MASLD/ MAFLD and ALD 2	Tomohide Kurahashi	Early Weight Response Identifies a High-Risk Phenotype in MASLD Patients Treated with Tirzepatide	Friday September 18, 2026	18:12-18:48	18:30	18:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 29	10186	Poster	MASLD/ MAFLD and ALD 2	Meti Metiani	Pnpla3 Rs738409 as a Genetic Driver of Mafld in Type 2 Diabetes Mellitus: a Systematic Review and Meta-Analysis	Friday September 18, 2026	18:12-18:48	18:36	18:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 29	10158	Poster	MASLD/ MAFLD and ALD 2	Sae Kyung Joo	Sex-Specific Determinants of Fibrosis Progression in MASLD: the Role of Menopause and Endogenous Estrogen Exposure	Friday September 18, 2026	18:12-18:48	18:42	18:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 30	10167	Poster	MASLD/ MAFLD and ALD 3	Soon Kyu Lee	Swe Performs Comparably to Vete in a Fib-4 Based Two-Step Risk Stratification Strategy for MASLD	Saturday September 19, 2026	15:30-16:00	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 30	10359	Poster	MASLD/ MAFLD and ALD 3	Dan Nakano	An Association of Covert Hepatic Encephalopathy with Non-Elderly and MASLD in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Data-Mining Analyses	Saturday September 19, 2026	15:30-16:00	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 30	10260	Poster	MASLD/ MAFLD and ALD 3	Ryotaro Sakamori	Clinical Event Risk in Patients with MASLD: Findings from a Prospective Multicenter Registry	Saturday September 19, 2026	15:30-16:00	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 30	10007	Poster	MASLD/ MAFLD and ALD 3	Hana Park	Differential Cancer Risks and Noninvasive Predictors in MASLD, Metald, and Ald: a Longitudinal Analysis	Saturday September 19, 2026	15:30-16:00	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 30	10087	Poster	MASLD/ MAFLD and ALD 3	Ryohei Yoshino	Inhibition of Polyamine Oxidation Modulates Hepatic Lipid Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease	Saturday September 19, 2026	15:30-16:00	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 31	10046	Poster	MASLD/ MAFLD and ALD 4	Kaede Fujita	Imeglimin in MASLD with Type 2 Diabetes: a Pilot Study on Hepatic and Metabolic Improvements	Saturday September 19, 2026	15:00-15:36	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 31	10142	Poster	MASLD/ MAFLD and ALD 4	Inas Karimi	Hepatorenal Crosstalk in Metabolic Syndrome: Nafld/masld as an Independent Risk Factor for Ckd	Saturday September 19, 2026	15:00-15:36	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 31	10067	Poster	MASLD/ MAFLD and ALD 4	Jacqueline Kwa	Raising MASLD Awareness for Early Prevention: a Public Health Education Initiative in Singapore	Saturday September 19, 2026	15:00-15:36	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 31	10130	Poster	MASLD/ MAFLD and ALD 4	Hideto Yuruki	Utility of the Fatty Liver Index as a Predictor of Hepatic Steatosis in Patients with Ald/metald	Saturday September 19, 2026	15:00-15:36	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 31	10151	Poster	MASLD/ MAFLD and ALD 4	Hery Djagat Purnomo	Altered Gut Microbial Taxa Are Associated with Metabolically Associated Fatty Liver Disease in Indonesian Adults : a Preliminary Study	Saturday September 19, 2026	15:00-15:36	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 31	10245	Poster	MASLD/ MAFLD and ALD 4	Tatia Khachidze	The Role of Probiotics and Prebiotics in the Management of MASLD: Aclinical Perspective	Saturday September 19, 2026	15:00-15:36	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 32	10379	Poster	MASLD/ MAFLD and ALD 5	Sung Jun Park	Comparison of Effectiveness Between Phentermine/topiramate and Liraglutide in Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease	Saturday September 19, 2026	15:36-16:12	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 32	10380	Poster	MASLD/ MAFLD and ALD 5	Mana Takano	Comparison of Liver Fibrosis Assessment by Shear Wave Elastography and Liver Biopsy	Saturday September 19, 2026	15:36-16:12	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 32	10366	Poster	MASLD/ MAFLD and ALD 5	Takashi Nishimura	Prediction of Hepatocellular Carcinoma Development in Patients with Alcohol-Related Liver Disease Using the Fib-3 Index, Fib-4 Index, and Vibration-Controlled Transient Elastography	Saturday September 19, 2026	15:36-16:12	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 32	10293	Poster	MASLD/ MAFLD and ALD 5	Junichi Hanatani	Efficacy and Safety of Nalmefene on Alcohol Consumption, Liver Function, and Gut Microbiota in Alcohol-Related Liver Disease	Saturday September 19, 2026	15:36-16:12	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 32	10068	Poster	MASLD/ MAFLD and ALD 5	Masafumi Haraguchi	Impact of Extracellular Fluid Retention on Bioelectrical Impedance-Based Muscle Mass Assessment in Patients with Steatotic Liver Disease-Related Cirrhosis: a Ct-Validated Study	Saturday September 19, 2026	15:36-16:12	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 32	10015	Poster	MASLD/ MAFLD and ALD 5	Vu Van Khien	Yttrium-90 Transarterial Radioembolization for Hepatocellular Carcinoma: Summary of 10 Years from Two Centers in Vietnam	Saturday September 19, 2026	15:36-16:12	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 33	10161	Poster	Hepatitis B 1	Kengo Watanabe	Differential Impact of Steatotic Liver Disease on Liver Fibrosis Progression According to Hepatitis B Virus DNA Levels in Untreated Patients with Chronic Hepatitis B Virus Infection	Friday September 18, 2026	17:00-17:30	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 33	10281	Poster	Hepatitis B 1	Esraa Kamal	High Throughput Identification of a Potent Inhibitor of Hepatitis B Virus Infection	Friday September 18, 2026	17:00-17:30	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 33	10341	Poster	Hepatitis B 1	Taotao Yan	Antiviral Therapies Are Under-Utilized in Patients with Hepatitis B-Related Hepatocellular Carcinoma Despite Substantial Survival Benefits	Friday September 18, 2026	17:00-17:30	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 33	10059	Poster	Hepatitis B 1	Eiichi Ogawa	Long-Term Clinical Impact of MASLD After Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B	Friday September 18, 2026	17:00-17:30	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 33	10073	Poster	Hepatitis B 1	Kathryn Effendi	Implementation of the Anrs 0562s Hipocamp Study in Vietnam: an International Collaborative Pilot Study on the Prevention of Mother-To-Child Transmission of Hepatitis B Virus (HBV)	Friday September 18, 2026	17:00-17:30	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 34	10021	Poster	Hepatitis B 2	Arjun Maria	Spectrum and Clinical Impact of Liver Involvement in Children Hospitalized with Respiratory Viral Infections	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 34	10086	Poster	Hepatitis B 2	Bunga P Ramadhani	Longitudinal Assessment of Hepatitis B Virus-Specific B Cells Before and After Nucleos(t)ide Therapy in Chronic Hepatitis B Patients	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 34	10162	Poster	Hepatitis B 2	Kotaro Doi	Longitudinal Increase in Fib-4 Index and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogues: a Multicenter Study	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 34	10099	Poster	Hepatitis B 2	Yohei Shirakami	Inhibition of Indoleamine 2,3-Dioxygenase Enhances Immune Responses to a Therapeutic Vaccine for Chronic Hepatitis B	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 34	10317	Poster	Hepatitis B 2	Takashi Honda	Association Between Hepatitis B Virus Mutation Rates and Clinical Outcomes in Chronic Hepatitis B	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 35	10093	Poster	Hepatitis B/ Virus	Keisuke Amano	Diagnostic Accuracy of a Clinically Accessible Itact-Based HCV Core Antigen Assay in a Japanese Cohort	Saturday September 19, 2026	15:30-16:06	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 35	10154	Poster	Hepatitis B/ Virus	Seiichi Mawatari	Cause-Specific Standardized Mortality Ratios in Patients After HCV Eradication with Direct-Acting Antivirals	Saturday September 19, 2026	15:30-16:06	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 35	10292	Poster	Hepatitis B/ Virus	Hiroyuki Kobayashi	Community-Based Hepatitis B Virus Screening Identifies Previously Undiagnosed Patients Requiring Antiviral Therapy in a Rural Japanese Population: the Nagawa Project	Saturday September 19, 2026	15:30-16:06	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 35	10126	Poster	Hepatitis B/ Virus	Tetsuya Hosaka	Latest Profiles of Qhbsag Among Patients Continuing Long-Term Nuc Treatment in Japan	Saturday September 19, 2026	15:30-16:06	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 35	10117	Poster	Hepatitis B/ Virus	Ekram Hasanin	Global Trends in Liver Cancer Attributable to Hepatitis B: Insights from the Globalburden of Disease 2023	Saturday September 19, 2026	15:30-16:06	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 35	10339	Poster	Hepatitis B/ Virus	Naoki Yamamoto	Development of a Highly Sensitive Rapid Test for the Detection of Hepatitis B Core-Related Antigen	Saturday September 19, 2026	15:30-16:06	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 36	10294	Poster	Liver Cirrhosis and Miscellaneous 1	Masaru Muraoka	A Study Using Mre and Neuropsychological Test Subtests for Stratification of Minimal Hepatic Encephalopathy Risk	Friday September 18, 2026	17:30-18:00	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 36	10318	Poster	Liver Cirrhosis and Miscellaneous 1	Shah Emtiaz Rahman	Spleen Stiffness Outperforms Conventional Fibrosis Markers for Predicting Esophageal Varices in Cirrhosis	Friday September 18, 2026	17:30-18:00	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 36	10326	Poster	Liver Cirrhosis and Miscellaneous 1	Ryuki Hashida	Safety and Feasibility of Supervised Low-Intensity Rehabilitation in Decompensated Liver Cirrhosis	Friday September 18, 2026	17:30-18:00	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 36	10134	Poster	Liver Cirrhosis and Miscellaneous 1	Huong Tu Lam	Multidrug-Resistant Pathogens and Treatment Non-Response in Spontaneous Bacterial Peritonitis Among Cirrhotic Patients: a Cohort Study from Vietnam	Friday September 18, 2026	17:30-18:00	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 36	10312	Poster	Liver Cirrhosis and Miscellaneous 1	Chikara Ogawa	Real-World Efficacy and Safety of Avatrombopag for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Invasive Procedures	Friday September 18, 2026	17:30-18:00	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 37	10289	Poster	Liver Cirrhosis and Miscellaneous 2	Yuki Motokawa	Vwf/adamts13 Ratio Improves the Diagnosis of Sarcopenia in Patients with Liver Cirrhosis	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 37	10295	Poster	Liver Cirrhosis and Miscellaneous 2	Marco Distefano	Claire: a Zero-Code, Uncertainty-Aware Llm Agent Transforming Cirrhosis Records into Actionable Intelligence for Liver Cancer Control	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 37	10345	Poster	Liver Cirrhosis and Miscellaneous 2	Natsuko Nishiyama	Evaluation of Portal Venous Hemodynamics in Portal Hypertension Using MRI	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 37	10203	Poster	Liver Cirrhosis and Miscellaneous 2	Yasuteru Kondo	Partial Splenic Embolization Improves Hepatic Reserve and Nlr, Supporting Multidisciplinary Treatment for Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 37	10008	Poster	Liver Cirrhosis and Miscellaneous 2	Hideko Ohama	Extended Five-Year Outcomes of First-Line Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: a Multicenter Real-World Study	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 38	10175	Poster	Liver Cirrhosis and Miscellaneous 3	Ryosuke Imado	Comparison of Therapeutic Efficacy Between Rifaximin and L-Carnitine for Hyperammonemia in Liver Cirrhosis: a Multicenter Retrospective Study Focusing on Long-Term Event Prevention	Saturday September 19, 2026	15:30-16:06	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 38	10196	Poster	Liver Cirrhosis and Miscellaneous 3	Yoji Ishizu	Association of Neuropsychological Test Abnormalities, Polypharmacy, and Liver Functional Reserve with Medication Understanding in Patients with Liver Disease	Saturday September 19, 2026	15:30-16:06	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 38	10106	Poster	Liver Cirrhosis and Miscellaneous 3	Minji Kim	Independent Association Between Serum Mac-2 Binding Protein Glycosylation Isomer and Fibroscan-Measured Liver Stiffness	Saturday September 19, 2026	15:30-16:06	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 38	10364	Poster	Liver Cirrhosis and Miscellaneous 3	Zannatul Habiba	Beyond Routine Blood Counts: Neutrophil-To-Lymphocyte Ratio as a Simple Predictor of Liver Cirrhosis Severity a Cross-Sectional Study from Bangladesh	Saturday September 19, 2026	15:30-16:06	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 38	10064	Poster	Liver Cirrhosis and Miscellaneous 3	Manabu Hayashi	Diabetes Mellitus and Prognosis in Cirrhotic Patients Experienced Overt Hepatic Encephalopathy	Saturday September 19, 2026	15:30-16:06	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 38	10050	Poster	Liver Cirrhosis and Miscellaneous 3	Ken Sato	Strategic Principles for Global HCV Elimination: a Comparative Analysis of 12 Countries on Track to Meet Who Targets	Saturday September 19, 2026	15:30-16:06	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 39	10125	Poster	Epidemiology and Liver disease 1	Kazuya Okushin	Selective Testing Recommendation Considering Clinical Timelines Improve Opportunities for Hepatitis C Diagnosis	Friday September 18, 2026	17:00-17:36	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 39	10000	Poster	Epidemiology and Liver disease 1	Ming-Lung Yu	Real-World Effectiveness and Safety of 8-Week Glecaprevir/pibrentasvir for Pwld and HIV Patients from Taiwan Nationwide HCV Registry	Friday September 18, 2026	17:00-17:36	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 39	10265	Poster	Epidemiology and Liver disease 1	Vinh H Vu	Worse Long-Term Clinical Outcome After Hepatitis C Cure Among People Who Inject Drugs Living with HIV in Vietnam	Friday September 18, 2026	17:00-17:36	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 39	10009	Poster	Epidemiology and Liver disease 1	Atsushi Ono	Metabolic Dysfunction-Associated Steatotic Liver Disease Increases the Risk of Hepatocellular Carcinoma After Sustained Virologic Response in Chronic Hepatitis C	Friday September 18, 2026	17:00-17:36	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 39	10247	Poster	Epidemiology and Liver disease 1	Tsubasa Tsutsumi	Low Muscle Mass Across Ckm Stages: Cross-Population Mediation, Mortality, and Multi-Omics Evidence	Friday September 18, 2026	17:00-17:36	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 39	10060	Poster	Epidemiology and Liver disease 1	K. M. Shakir Ahmed	Prevalence of Hepatitis C Virus Infection Among Prison Inmates: A Cross-Sectional Study at Dhaka Central Jail, Bangladesh	Friday September 18, 2026	17:00-17:36	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 40	10361	Poster	Epidemiology and Liver disease 2	Joengin Lee	Risk of Mental, Behavioral, and Neurodevelopmental Disorders in Offspring Associated with Maternal Liver Cancer Before Pregnancy	Friday September 18, 2026	17:36-18:06	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 40	10240	Poster	Epidemiology and Liver disease 2	Masahito Nakano	Nationwide Trends in Liver Stiffness Measurement in Japan: Real-World Evidence from the National Database of Health Insurance Claims	Friday September 18, 2026	17:36-18:06	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 40	10081	Poster	Epidemiology and Liver disease 2	Haruka Taninaka	Non-Cirrhotic Portal Hypertension Caused by a Hepatic Hemangioma-Associated Intrahepatic Arteriportal Shunt Presenting with Ruptured Esophageal Varices Successfully Treated with Transarterial Embolization	Friday September 18, 2026	17:36-18:06	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 40	10228	Poster	Epidemiology and Liver disease 2	Hirayuki Enomoto	Etiological Transitions in Patients with Liver Cirrhosis and Hcc-Complicated Cirrhosis: a Single-Center Study from an Institution in a District Area with a High Prevalence of Viral Hepatitis	Friday September 18, 2026	17:36-18:06	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 40	10207	Poster	Epidemiology and Liver disease 2	Chi-Yu Lee	Clinical Significance of Durable Response to Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma	Friday September 18, 2026	17:36-18:06	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 41	10074	Poster	Epidemiology and Liver disease 3	Amjad Khan	Real-World Sorafenib Adverse Events and Quality-Of-Life Trajectories in Advanced Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 41	10180	Poster	Epidemiology and Liver disease 3	Maiko Nagaoka	Serum Mac-2 Binding Protein Glycosylation Isomer Is Associated with Physical Frailty in Community-Dwelling Older Adults	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 41	10179	Poster	Epidemiology and Liver disease 3	Satoru Kakizaki	Long-Term Outcomes of Sofosbuvir/velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: a Retrospective Multicenter Cohort Study	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 41	10212	Poster	Epidemiology and Liver disease 3	Ryoko Asari	Nationwide Integration of Hepatitis B into Antenatal Care for Triple Elimination of Mother-To-Child Transmission of HIV, Syphilis, and Hepatitis B in the Gambia: Early Lessons from Global Fund-Supported Scale-Up	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 41	10283	Poster	Epidemiology and Liver disease 3	Kenta Suzuki	Long-Term Outcomes in Patients with Decompensated Cirrhosis Who Achieved SVR: a Multicenter Study	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 42	10133	Poster	Epidemiology and Liver disease 4	Hiroki Sugiura	Clinical Utility of a Combined HCV Antibody/antigen Assay: Comparison with a Single Antibody Assay and a Prospective Study	Saturday September 19, 2026	15:30-16:00	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 42	10327	Poster	Epidemiology and Liver disease 4	Xiang Zhou	Twenty-Year Trends in Liver Biopsy Practice: from Viral Hepatitis to Steatotic Liver Disease and Autoimmune Liver Diseases	Saturday September 19, 2026	15:30-16:00	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 42	10188	Poster	Epidemiology and Liver disease 4	Kazuhiro Kawata	Awareness of Viral Hepatitis Among Junior and Senior High School Students and the Effectiveness of a School-Based Educational Program: a Large-Scale Longitudinal Study	Saturday September 19, 2026	15:30-16:00	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 42	10370	Poster	Epidemiology and Liver disease 4	Vikas Sharma	Smartcare-Lc: an AI Driven Digital Ecosystem for Personalized Precision Oncology in Liver Cancer	Saturday September 19, 2026	15:30-16:00	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 42	10301	Poster	Epidemiology and Liver disease 4	Takako Inoue	Improving Medical Attendance Confirmation for Hepatitis Testing-Positive Individuals: a Seven-Year Study in Aichi, Japan	Saturday September 19, 2026	15:30-16:00	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 43	10159	Poster	Surgical Treatment 1	Tzu Ya Lien	Impact of Initial Surgery on Survival Outcomes in Combined Hepatocellular-Cholangiocellular Carcinoma: a Single-Center Retrospective Analysis	Friday September 18, 2026	18:00-18:30	18:00	18:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 43	10038	Poster	Surgical Treatment 1	Takahisa Fujikawa	Multidisciplinary Treatment Combining Systemic Biologic Therapy and Minimally Invasive Hepatectomy for Borderline-Resectable Hepatocellular Carcinoma: an Analysis of 10 Consecutive Cases	Friday September 18, 2026	18:00-18:30	18:06	18:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 43	10027	Poster	Surgical Treatment 1	Arjun Maria	Non-Destructive Ebv-Associated Ptd Presenting with Gastrointestinal Bleeding in a Post-Liver Transplant Child: Diagnostic and Therapeutic Challenges	Friday September 18, 2026	18:00-18:30	18:12	18:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 43	10321	Poster	Surgical Treatment 1	Masaaki Hidaka	Liver Resection Following Multidisciplinary Treatment for Borderline Resectable Hepatocellular Carcinoma (Br2): a Report of Four Cases	Friday September 18, 2026	18:00-18:30	18:18	18:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 43	10181	Poster	Surgical Treatment 1	Aswanth Ks	Impact of Sarcopenia in Early Outcomes of Pediatric Liver Transplantation: a Single-Centre Cohort Study	Friday September 18, 2026	18:00-18:30	18:24	18:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 44	10349	Poster	Surgical Treatment 2	Shinji Itoh	Effect of Curative Resection After Atezolizumab Plus Bevacizumab on Outcome in Hepatocellular Carcinoma	Friday September 18, 2026	17:24-18:00	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 44	10258	Poster	Surgical Treatment 2	Shinya Hayami	Perioperative Detection of Second Primary Malignancies in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma	Friday September 18, 2026	17:24-18:00	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 44	10018	Poster	Surgical Treatment 2	Tomoko Tadokoro	Recurrent Intraoperative Bradycardia During Radiofrequency Ablation for Hepatocellular Carcinoma	Friday September 18, 2026	17:24-18:00	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 44	10012	Poster	Surgical Treatment 2	Ekram Hasanin	Novel Trends in Liver Transplantation for MASLD and Ald: Emerging Epidemiology, Allocation& Post-Transplant Challenges	Friday September 18, 2026	17:24-18:00	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 44	10221	Poster	Surgical Treatment 2	Yuwa Ando	Hepatic Resection Following Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: a Single-Center Experience and Clinical Implications	Friday September 18, 2026	17:24-18:00	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 44	10263	Poster	Surgical Treatment 2	T Oga	A Case of a Rapidly Growing Inflammatory Hepatocellular Adenoma Treated with Robot-Assisted Liver Resection	Friday September 18, 2026	17:24-18:00	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 45	10032	Poster	Basic & Translational research 1	Tuan Anh Pham	Cdc80 as a Novel Marker and Therapeutic Target in Liver Fibrosis: a Single-Cell RNA Sequencing Study	Friday September 18, 2026	17:00-17:24	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 45	10110	Poster	Basic & Translational research 1	Charupong Saengboonmee	The Impact of Adiposity and Leptin Signaling on Hepatocellular Carcinoma Progression and Patient Prognosis	Friday September 18, 2026	17:00-17:24	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 45	10236	Poster	Basic & Translational research 1	Haruna Noguchi	Prime Editing Enables Isogenic Modeling of Pnpla3-I148m-Associated Lipotoxicity in Hepatocytes	Friday September 18, 2026	17:00-17:24	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 45	10143	Poster	Basic & Translational research 1	Yan Zhang	Akkermansia-Mediated Nutritional Preconditioning Alleviates Cholestatic Liver Fibrosis via the I3a-Ahr-Nrf2 Axis	Friday September 18, 2026	17:00-17:24	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 46	10047	Poster	Basic & Translational research 2	Yuki Kunimune	Quantitative Pcr-Based Measurement of Serum Methylated Sept9 , Hoxa1 , and Sst Achieves Equivalent Diagnostic Performance to Digital PCR for Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:00	15:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 46	10284	Poster	Basic & Translational research 2	Yutaka Yasui	Comprehensive Genomic Profiling in Advanced Hepatocellular Carcinoma: Real-World Cohort	Saturday September 19, 2026	15:00-15:30	15:06	15:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 46	10104	Poster	Basic & Translational research 2	Yang Jae Yoo	Machine Learning Based Identification of Exosomal Mir-30a-5p as a Predictive Biomarker for Atezolizumab Plus Bevacizumab Response in Advanced Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:12	15:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 46	10138	Poster	Basic & Translational research 2	Tomoyuki Satake	Clinical Outcomes of Cabozantinib During the Ici Era	Saturday September 19, 2026	15:00-15:30	15:18	15:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 46	10264	Poster	Basic & Translational research 2	Naoto Izumi	Long-Term Outcomes After Subsequent Anticancer Treatment for Ruptured Hepatocellular Carcinoma	Saturday September 19, 2026	15:00-15:30	15:24	15:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 47	10280	Poster	Miscellaneous and Case Reports 1	Agus Sukanto	From Presumed Hepatocellular Carcinoma to Intrahepatic Cholangiocarcinoma: the Impact of Tissue Diagnosis on Clinical Management and Treatment Outcome	Friday September 18, 2026	17:00-17:30	17:00	17:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 47	10267	Poster	Miscellaneous and Case Reports 1	Duong Thuy Phung	Stereotactic Body Radiotherapy (Sbrt) Achieves Lasting Response After Sequential TACE and Multiline Systemic Therapy Failure in Intermediate-Stage Hepatocellular Carcinoma: a Case Report	Friday September 18, 2026	17:00-17:30	17:06	17:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 47	10279	Poster	Miscellaneous and Case Reports 1	Tri Hartanto	Occult Satellite Lesions in Low-Afp Hepatocellular Carcinoma: Implications of Afp-Negative Phenotypes in Early-Stage Disease	Friday September 18, 2026	17:00-17:30	17:12	17:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 47	10313	Poster	Miscellaneous and Case Reports 1	Yasuhide Motoyoshi	Two Cases of Cytokine Release Syndrome (Crs) During Combination Immunotherapy for Unresectable Hepatocellular Carcinoma	Friday September 18, 2026	17:00-17:30	17:18	17:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 47	10026	Poster	Miscellaneous and Case Reports 1	Shiho Miyase	Impact of Liver Steatosis on Hepatocarcinogenesis in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Analog Therapy	Friday September 18, 2026	17:00-17:30	17:24	17:30	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 48	10237	Poster	Miscellaneous and Case Reports 2	Song Huy Nguyen Dinh	Hepatocellular Carcinoma (HCC): Challenges in Screening, Diagnosis, and Management in Vietnam	Friday September 18, 2026	17:30-18:00	17:30	17:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 48	10257	Poster	Miscellaneous and Case Reports 2	Chang-Chieng Soon	Immune-Mediated Clopidogrel-Induced Drug-Induced Liver Injury Confirmed by Drug-Specific Lymphocyte Transformation Test: a Case Report and Literature Review	Friday September 18, 2026	17:30-18:00	17:36	17:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 48	10375	Poster	Miscellaneous and Case Reports 2	Ngoc Minh Nguyen	Hepatitis B Prevention Knowledge and Attitudes Among Medical Students in Low- and Middle-Income Countries: a Systematic Review	Friday September 18, 2026	17:30-18:00	17:42	17:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 48	10157	Poster	Miscellaneous and Case Reports 2	Balaussa Absamat	Self-Reported Hepatitis B Vaccination Status and Knowledge, Attitudes, and Practices Towards Hepatitis B Among Medical Students in Kazakhstan: a Cross-Sectional Study	Friday September 18, 2026	17:30-18:00	17:48	17:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 48	10061	Poster	Miscellaneous and Case Reports 2	Akinobu Tawada	Overcoming International Disparities in Accessibility for Anticancer Drugs: an Ecological Study Using Country-Level Data	Friday September 18, 2026	17:30-18:00	17:54	18:00	Presentation: 4min. QA Time: 2min. Total: 6min.

Group	No	Style	Session Name	Name	Title of Abstract	Session Date	Session Time	Presentation Start	Presentation End	Presentation Time
Group 49	10248	Poster	Miscellaneous and Case Reports 3	Tanusree Saha Mumu	Hepatic Amyloidosis Presenting as Cholestatic Liver Disease with Portal Hypertension: a Case Report	Saturday September 19, 2026	15:30-16:00	15:30	15:36	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 49	10062	Poster	Miscellaneous and Case Reports 3	Yuri Sakamoto	A Case of Sclerosing Cholangitis That Was Difficult to Differentiate from Intrahepatic Cholangiocarcinoma	Saturday September 19, 2026	15:30-16:00	15:36	15:42	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 49	10282	Poster	Miscellaneous and Case Reports 3	Kazuya Minamoto	A Case of Pet-Negative Intrahepatic Cholangiocarcinoma That Was Difficult to Diagnose	Saturday September 19, 2026	15:30-16:00	15:42	15:48	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 49	10082	Poster	Miscellaneous and Case Reports 3	Shohei Miyabe	A Case of Intrahepatic Cholangiocarcinoma Achieving Remarkable Tumor Regression via Heavy-Ion Radiotherapy Followed by Immunotherapy	Saturday September 19, 2026	15:30-16:00	15:48	15:54	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 49	10148	Poster	Miscellaneous and Case Reports 3	Taro Shibuki	Sex-Based Outcomes of First-Line Systemic Therapy in Advanced Intrahepatic Cholangiocarcinoma	Saturday September 19, 2026	15:30-16:00	15:54	16:00	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 50	10033	Poster	Miscellaneous and Case Reports 4	Babylyn Oab	Fever Without Focus: an Atypical Presentation of Hypervirulent Klebsiella Pneumoniae Liver Abscess in Newly Diagnosed Diabetes Mellitus	Saturday September 19, 2026	16:00-16:30	16:00	16:06	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 50	10191	Poster	Miscellaneous and Case Reports 4	Tatsuo Kanda	Acute-On-Chronic Liver Failure Following Pneumonia in an Elderly Woman with Metabolic Dysfunction-Associated Steatotic Liver Cirrhosis	Saturday September 19, 2026	16:00-16:30	16:06	16:12	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 50	10122	Poster	Miscellaneous and Case Reports 4	Takeshi Chida	HBV Genomic Sequences Detected by Comprehensive Genomic Profiling Provided a Clue to the Diagnosis of Metastatic Hepatocellular Carcinoma	Saturday September 19, 2026	16:00-16:30	16:12	16:18	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 50	10337	Poster	Miscellaneous and Case Reports 4	Tatsuo Kanda	Pemafibrate Effectively Prevented Liver Dysfunction in Young Female with Anorexia Nervosa	Saturday September 19, 2026	16:00-16:30	16:18	16:24	Presentation: 4min. QA Time: 2min. Total: 6min.
Group 50	10356	Poster	Miscellaneous and Case Reports 4	Hirotoشي Ebinuma	A Case of HCC Presenting with Gastric Ulcers by VEGF Inhibition	Saturday September 19, 2026	16:00-16:30	16:24	16:30	Presentation: 4min. QA Time: 2min. Total: 6min.